LIXTE BIOTECHNOLOGY HOLDINGS, INC.
About LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2015
- $200.0K
- Net income
- -$6.1M
- Total assets
- $12.7M
- Market cap
- $121.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $5.1M
- Operating income
- -$5.1M
- Net income
- -$6.0M
- EPS (diluted)
- $-1.26
Balance sheet
- Total assets
- $12.7M
- Current assets
- $5.2M
- Total liabilities
- $1.8M
- Current liabilities
- $1.3M
- Shareholders’ equity
- $11.0M
Cash flow
- Operating cash flow
- -$3.1M
- Net cash flow
- -$3.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $121.7M
- EPS (diluted)
- $-1.26
- Shares outstanding
- 18.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 5, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $6.1M in FY2015.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LIXTE BIOTECHNOLOGY HOLDINGS, INC..
Write a review
News about LIXTE BIOTECHNOLOGY HOLDINGS, INC.
News & sentiment via Polygon.io
